Animal Models Core

动物模型核心(核心C)的主要任务是进行动物挑战试验，以支持 RMRCE内部、其他RCEs以及与其他政府、私人和 学术机构。这些服务将根据调查人员和计划的需求量身定做，范围 从简单的发病率和死亡率实验，到涉及气溶胶挑战的更复杂的研究， 紧张的临床评估(如随时间抽血、遥测监测、血液学)、尸检、 组织病理学评价和器官病原体载量。这项工作将向调查人员收取服务费， RCE和美国政府调查人员与非RCE学术人员的费用时间表不同 机构和商业实体。除了主要关注服务之外，核心C级人员还将： 1)协助调查人员设计适当的动物实验，包括撰写动物用法， 选择提案中的代理人和动物预算部分。这被视为一项有价值和重要的服务 这最终将增加项目收入，并为生物防御努力做出贡献。 2)建立新的并增强现有的啮齿动物模型，以响应或预期研究人员的需求。 第一年的目标之一将是为选定的细菌病原体确定挑战后的最大间隔 开始大剂量(相关)抗生素治疗将使患者存活；这些数据将 提供参考点，以协助设计和进行试验，以评估将被 适用于曝光后。增强当前模型的另一个示例将是将 血液学和临床化学改变与疾病发病机制相关；再次，这将是 在评估药物或免疫干预的有效性方面有价值。 3)推广使用非啮齿动物模型治疗某些病原体。这样的模型可以提供大量的 血清和其他样本作为参考试剂并测试诊断平台，以提供天然宿主 疫苗和治疗试验的基础，并允许在旨在 评估人类使用的治疗方法。核心C在提供这种能力的RCE中具有独特的地位。 核心C将支持RMRCE关于免疫调节、佐剂和 疫苗(IRF 1)、细菌治疗(IRF 2)和病毒治疗(IRF 3)。它的资源将是 由RPS 1.5、1.6、1.7、1.8、2.3、2.6、2.7、3.3、3.5和3.6使用。

The primary mission of the Animal Models Core (Core C) is to conduct animal challenge trials in support of studies by investigators within the RMRCE, at other RCEs and with other governmental, private and academic institutions. These services will be tailored to the needs of the investigator and program, ranging from simple morbidity and mortality experiments, to more complex studies involving aerosol challenges, intense clinical evaluation (i.e. blood sampling over time, telemetric monitoring, hematology), necropsy, histopathologic evaluation and organ pathogen loads. The work will be fee-for-service to investigators, with different fee schedules for RCE and US government investigators versus those from non-RCE academic institutions and commercial entities. In addition to this primary focus on service, Core C personnel will: 1) Assist investigators in the design of appropriate animal experiments, including writing the animal use, select agent and animal budget portions of proposals. This is viewed as a valuable and important service which will ultimately augment program income and contribute to the biodefense effort. 2) Establish new, and enhance existing, rodent models in response to or anticipation of investigator needs. One goal for Year 1 will be to establish, for selected bacterial pathogens, the maximum interval postchallenge at which initiation of high-dose (relevant) antibiotic therapy will allow survival; these data will provide reference points to assist in designing and conducting trials to evaluate therapeutic agents to be applied post-exposure. Another example of enhancing current models will be to characterize the hematologic and clinical chemistry alterations associated with disease pathogenesis; again, this will be valuable in evaluating efficacy of pharmacologic or immunologic interventions. 3) Promote the use of non-rodent models for certain pathogens. Such models could provide large quantities of serum and other samples as reference reagents and to test diagnostic platforms, to provide natural host bases for vaccine and therapeutic trials, and to allow realistic ICU-type monitoring in trials designed to evaluate therapies for human use. Core C is uniquely positioned among RCEs to provide such capabilities. Core C will support all three of the RMRCE Integrated Research Foci on Immunomodulation, Adjuvants and Vaccines (IRF 1), Bacterial Therapeutics (IRF 2), and Viral Therapeutics (IRF 3). Its resources will be utilized by RPs 1.5, 1.6, 1.7, 1.8, 2.3, 2.6, 2.7, 3.3, 3.5 and 3.6.